Ascendis Pharma (ASND) Misses Q2 EPS by 55c; cuts Skytrofa revenue outlook

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR1.91), EUR0.55 worse than the analyst estimate of (EUR1.36). Revenue for the quarter came in at EUR36 million versus the consensus estimate of EUR83.7 million.

The company sees Skytrofa revenue EU220 million to EU240 million, down from the prior range of EU320 million to EU340 million, vs. estimated EU350.7 million

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• JPMorgan Starts Zensho Holdings (7550:JP) at Overweight
• LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
• Stifel Canada Starts Custom Health Holdings (CHLT:CN) at Buy